000162924 001__ 162924
000162924 005__ 20240320115515.0
000162924 0247_ $$2pmc$$apmc:PMC8795231
000162924 0247_ $$2doi$$a10.1177/0271678X211049820
000162924 0247_ $$2pmid$$apmid:34590894
000162924 0247_ $$2ISSN$$a0271-678X
000162924 0247_ $$2ISSN$$a1559-7016
000162924 0247_ $$2altmetric$$aaltmetric:115549204
000162924 037__ $$aDZNE-2021-01576
000162924 041__ $$aEnglish
000162924 082__ $$a610
000162924 1001_ $$0P:(DE-2719)2811871$$aArboit, Alberto$$b0$$eFirst author$$udzne
000162924 245__ $$aThe cholinergic system modulates negative BOLD responses in the prefrontal cortex once electrical perforant pathway stimulation triggers neuronal afterdischarges in the hippocampus.
000162924 260__ $$aLondon$$bSage$$c2022
000162924 3367_ $$2DRIVER$$aarticle
000162924 3367_ $$2DataCite$$aOutput Types/Journal article
000162924 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1655199038_923
000162924 3367_ $$2BibTeX$$aARTICLE
000162924 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000162924 3367_ $$00$$2EndNote$$aJournal Article
000162924 500__ $$a(CC BY)
000162924 520__ $$aRepeated high-frequency pulse-burst stimulations of the rat perforant pathway elicited positive BOLD responses in the right hippocampus, septum and prefrontal cortex. However, when the first stimulation period also triggered neuronal afterdischarges in the hippocampus, then a delayed negative BOLD response in the prefrontal cortex was generated. While neuronal activity and cerebral blood volume (CBV) increased in the hippocampus during the period of hippocampal neuronal afterdischarges (h-nAD), CBV decreased in the prefrontal cortex, although neuronal activity did not decrease. Only after termination of h-nAD did CBV in the prefrontal cortex increase again. Thus, h-nAD triggered neuronal activity in the prefrontal cortex that counteracted the usual neuronal activity-related functional hyperemia. This process was significantly enhanced by pilocarpine, a mACh receptor agonist, and completely blocked when pilocarpine was co-administered with scopolamine, a mACh receptor antagonist. Scopolamine did not prevent the formation of the negative BOLD response, thus mACh receptors modulate the strength of the negative BOLD response.
000162924 536__ $$0G:(DE-HGF)POF4-351$$a351 - Brain Function (POF4-351)$$cPOF4-351$$fPOF IV$$x0
000162924 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000162924 650_7 $$2Other$$aCerebral blood volume (CBV)
000162924 650_7 $$2Other$$aelectrophysiology
000162924 650_7 $$2Other$$anegative BOLD response
000162924 650_7 $$2Other$$apilocarpine
000162924 650_7 $$2Other$$ascopolamine
000162924 650_2 $$2MeSH$$aAnimals
000162924 650_2 $$2MeSH$$aCerebrovascular Circulation
000162924 650_2 $$2MeSH$$aHippocampus: blood supply
000162924 650_2 $$2MeSH$$aHippocampus: metabolism
000162924 650_2 $$2MeSH$$aHyperemia: metabolism
000162924 650_2 $$2MeSH$$aMale
000162924 650_2 $$2MeSH$$aMuscarinic Agonists: pharmacology
000162924 650_2 $$2MeSH$$aMuscarinic Antagonists: pharmacology
000162924 650_2 $$2MeSH$$aNeurons: metabolism
000162924 650_2 $$2MeSH$$aPerforant Pathway: blood supply
000162924 650_2 $$2MeSH$$aPerforant Pathway: metabolism
000162924 650_2 $$2MeSH$$aPilocarpine: pharmacology
000162924 650_2 $$2MeSH$$aPrefrontal Cortex: blood supply
000162924 650_2 $$2MeSH$$aPrefrontal Cortex: metabolism
000162924 650_2 $$2MeSH$$aRats
000162924 650_2 $$2MeSH$$aRats, Wistar
000162924 650_2 $$2MeSH$$aScopolamine: pharmacology
000162924 7001_ $$0P:(DE-2719)2278716$$aKrautwald, Karla$$b1$$udzne
000162924 7001_ $$0P:(DE-2719)2810456$$aAngenstein, Frank$$b2$$eLast author$$udzne
000162924 773__ $$0PERI:(DE-600)2039456-1$$a10.1177/0271678X211049820$$gp. 0271678X2110498 -$$n2$$p364-380$$tJournal of cerebral blood flow & metabolism$$v42$$x1559-7016$$y2022
000162924 8564_ $$uhttps://journals.sagepub.com/doi/10.1177/0271678X211049820?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
000162924 8564_ $$uhttps://pub.dzne.de/record/162924/files/DZNE-2021-01576.pdf$$yOpenAccess
000162924 8564_ $$uhttps://pub.dzne.de/record/162924/files/DZNE-2021-01576.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000162924 909CO $$ooai:pub.dzne.de:162924$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000162924 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811871$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000162924 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2278716$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000162924 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810456$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000162924 9131_ $$0G:(DE-HGF)POF4-351$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vBrain Function$$x0
000162924 9141_ $$y2022
000162924 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-10
000162924 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-10
000162924 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-10
000162924 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-04
000162924 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-10
000162924 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CEREBR BLOOD F MET : 2021$$d2022-11-10
000162924 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-04
000162924 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-10
000162924 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000162924 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-10
000162924 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-10
000162924 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ CEREBR BLOOD F MET : 2021$$d2022-11-10
000162924 915__ $$0StatID:(DE-HGF)0430$$2StatID$$aNational-Konsortium$$d2022-11-10$$wger
000162924 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-04
000162924 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000162924 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-10
000162924 9201_ $$0I:(DE-2719)1310004$$kAG Angenstein$$lFunctional Neuroimaging$$x0
000162924 980__ $$ajournal
000162924 980__ $$aVDB
000162924 980__ $$aUNRESTRICTED
000162924 980__ $$aI:(DE-2719)1310004
000162924 9801_ $$aFullTexts